NCT01229410

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.

Conditions

• Vitrectomy

Interventions

Type	Name	Description
DRUG	400 µg Brimonidine Tartrate Implant	400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
DRUG	200 µg Brimonidine Tartrate Implant	200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-05-01
• Completion: 2011-10-01
• First posted: 2010-10-27
• Last updated: 2013-08-05
• Results posted: 2013-08-05

Locations

2 sites across 2 countries: United States, Czechia